Hims & Hers Health, Inc. (NYSE:HIMS) Shares Sold by Metavasi Capital LP

Metavasi Capital LP trimmed its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 56.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 187,423 shares of the company's stock after selling 247,000 shares during the period. Hims & Hers Health comprises about 1.6% of Metavasi Capital LP's portfolio, making the stock its 17th biggest position. Metavasi Capital LP owned 0.09% of Hims & Hers Health worth $4,532,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in HIMS. Crewe Advisors LLC purchased a new position in shares of Hims & Hers Health in the 4th quarter valued at about $28,000. Raleigh Capital Management Inc. increased its stake in Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after purchasing an additional 1,100 shares during the last quarter. Blume Capital Management Inc. lifted its position in shares of Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after buying an additional 600 shares during the last quarter. Smartleaf Asset Management LLC lifted its position in Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after acquiring an additional 1,413 shares during the last quarter. Finally, Summit Securities Group LLC acquired a new stake in shares of Hims & Hers Health in the 4th quarter valued at about $38,000. Institutional investors and hedge funds own 63.52% of the company's stock.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 4,153 shares of the stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $35.30, for a total transaction of $146,600.90. Following the transaction, the insider now directly owns 161,497 shares in the company, valued at $5,700,844.10. This represents a 2.51 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Andrew Dudum sold 128,127 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $58.27, for a total transaction of $7,465,960.29. Following the completion of the sale, the chief executive officer now directly owns 97,687 shares of the company's stock, valued at $5,692,221.49. The trade was a 56.74 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 666,234 shares of company stock valued at $26,387,645. Insiders own 17.71% of the company's stock.

Hims & Hers Health Stock Performance

Shares of NYSE:HIMS traded up $4.82 during mid-day trading on Friday, hitting $40.98. 49,512,288 shares of the company traded hands, compared to its average volume of 16,802,829. The firm's 50 day simple moving average is $32.21 and its 200 day simple moving average is $31.49. The firm has a market cap of $9.10 billion, a P/E ratio of 93.14 and a beta of 1.65. Hims & Hers Health, Inc. has a 52-week low of $11.45 and a 52-week high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.02. The company had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on HIMS. Bank of America increased their price target on shares of Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a research note on Tuesday, April 29th. Leerink Partners lifted their price target on Hims & Hers Health from $24.00 to $40.00 and gave the company a "market perform" rating in a research note on Tuesday, February 25th. Truist Financial lowered their target price on shares of Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating on the stock in a research report on Thursday, April 10th. Piper Sandler lifted their price objective on Hims & Hers Health from $24.00 to $35.00 and gave the stock a "neutral" rating in a report on Tuesday, February 25th. Finally, Morgan Stanley lowered their price target on shares of Hims & Hers Health from $60.00 to $40.00 and set an "equal weight" rating on the stock in a research report on Tuesday, April 29th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $36.92.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.